Filing Flows › Elite Pharmaceuticals (ELTP) › Q1 FY27 › vs Q4 FY26
Elite Pharmaceuticals (ELTP) Q1 FY27 vs Q4 FY26 (quarter over quarter)
Elite Pharmaceuticals's revenue fell $8.4M (-21%) from $40.7M in Q4 FY26 to $32.4M in Q1 FY27. Gross margin 41.7% against 51.0% (-9.2 pts).
Elite Pharmaceuticals, Q1 FY27: revenue $32.4M (-20% year over year), operating margin 23.3%, net earnings $5.9M, operating cash flow $10.1M. The chart draws each line against Q4 FY26, the increases inside each band.
Margins
| Q1 FY27 | Q4 FY26 | Change | |
|---|---|---|---|
| Gross margin | 41.7% | 51.0% | -9.2 pts |
| Operating margin | 23.3% | 25.0% | -1.7 pts |
| Net margin | 18.3% | 45.3% | -27.0 pts |
| Free cash flow margin | 28.6% | 21.5% | +7.2 pts |
Every line
| Line | Q1 FY27 | Q4 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $32.4M | $40.7M | −$8.4M | -21% |
| Gross profit | $13.5M | $20.8M | −$7.3M | -35% |
| Cost of revenue | $18.8M | $20.0M | −$1.1M | -6% |
| Other income, net | $187K | $10.7M | −$10.5M | -98% |
| Operating profit | $7.5M | $10.2M | −$2.7M | -26% |
| Operating expenses | $6.0M | $10.6M | −$4.6M | -44% |
| Pre-tax earnings | $7.7M | $20.9M | −$13.1M | -63% |
| Research & development | $2.0M | $1.6M | $390K | +24% |
| General & admin | $3.5M | $7.7M | −$4.1M | -54% |
| Other operating costs | $396K | $1.2M | −$850K | -68% |
| Net earnings | $5.9M | $18.5M | −$12.6M | -68% |
| Income tax | $1.8M | $2.4M | −$587K | -25% |
| Depreciation | $253K | $252K | $1K | +0.4% |
| Share-based compensation | $28K | $29K | −$1K | -2% |
| Working capital & other | $3.9M | −$9.6M | $13.5M | — |
| Operating cash flow | $10.1M | $9.1M | $923K | +10% |
| Free cash flow (OCF − capex) | $9.3M | $8.7M | $512K | +6% |
| Capital expenditures | $809K | $398K | $411K | +103% |
Questions
How much did Elite Pharmaceuticals's revenue grow quarter over quarter in Q1 FY27?
Elite Pharmaceuticals's revenue fell $8.4M (-21%) from $40.7M in Q4 FY26 to $32.4M in Q1 FY27. Gross margin 41.7% against 51.0% (-9.2 pts).